{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:00:35Z","timestamp":1776394835458,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bond University Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The aim of this systematic review and meta-analysis was to identify the discontinuation rates, and incidence of adverse effects (AEs) for patients on prescribed oral darifenacin for the treatment of overactive bladder (OAB). PubMed, Embase, and Cochrane CENTRAL were searched for randomized controlled trials. A risk of bias assessment and a Grading of Recommendations Assessment, Development and Evaluation were used to assess the certainty of evidence. The primary outcome was OAB patient discontinuation and AEs in darifenacin and placebo groups, and reporting was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Seven studies of 2381 participants were included. The most reported AEs were dry mouth and constipation. There were more participants with dry mouth in the darifenacin group compared to the placebo (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001, moderate level of certainty) and a dose\u2013response pattern was observed. There was a higher rate of constipation in the darifenacin group than in the placebo group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001, high level of certainty), with evidence of a dose\u2013response pattern. There were no differences between the darifenacin group and the placebo group in total discontinuations (RR 0.93, 95% CI 0.72\u20131.20) or undefined discontinuations (RR 0.85, 95% CI 0.54\u20131.33). Studies were generally rated at low or unclear risk of bias for most domains. While patients prescribed darifenacin do experience a higher rate of side-effects, which increases with dose, they seem to be tolerated as both the intervention and placebo groups reported similar rates of discontinuation.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04806-4","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:43:55Z","timestamp":1767966235000},"page":"8645-8656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse effects and discontinuation rates for darifenacin in overactive urinary bladder: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0933-1952","authenticated-orcid":false,"given":"Vineesha","family":"Veer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8767-0268","authenticated-orcid":false,"given":"Felicity","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-9001","authenticated-orcid":false,"given":"Anna Mae","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-8301","authenticated-orcid":false,"given":"Christian","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"8","key":"4806_CR1","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1007\/s12325-020-01412-z","volume":"37","author":"RR Aparasu","year":"2020","unstructured":"Aparasu RR, Sura S, Earla JR, Shiozawa A, Ng DB, Schermer CR (2020) Antimuscarinic discontinuation in patients with overactive bladder in nursing homes: a retrospective study of medicare beneficiaries. Adv Ther 37(8):3584. https:\/\/doi.org\/10.1007\/s12325-020-01412-z","journal-title":"Adv Ther"},{"issue":"4","key":"4806_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/01.ju.0000155798.78911.57","volume":"173","author":"L Cardozo","year":"2005","unstructured":"Cardozo L, Dixon A (2005) Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 173(4):1214\u20131218. https:\/\/doi.org\/10.1097\/01.ju.0000155798.78911.57","journal-title":"J Urol"},{"issue":"10","key":"4806_CR3","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1185\/03007x226294","volume":"23","author":"C Chapple","year":"2007","unstructured":"Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A (2007) Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. CMRO 23(10):2347\u20132358. https:\/\/doi.org\/10.1185\/03007x226294","journal-title":"CMRO"},{"issue":"1","key":"4806_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/luts.12193","volume":"11","author":"Y-C Chuang","year":"2019","unstructured":"Chuang Y-C, Liu S-P, Lee K-S, Liao L, Wang J, Yoo TK, Chu R, Sumarsono B (2019) Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms 11(1):48\u201355. https:\/\/doi.org\/10.1111\/luts.12193","journal-title":"Low Urin Tract Symptoms"},{"issue":"4","key":"4806_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","volume":"45","author":"F Haab","year":"2004","unstructured":"Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45(4):420\u2013429. https:\/\/doi.org\/10.1016\/j.eururo.2004.01.008","journal-title":"Eur Urol"},{"issue":"1","key":"4806_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridr D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4\u201320. https:\/\/doi.org\/10.1002\/nau.20798","journal-title":"Neurourol Urodyn"},{"key":"4806_CR7","unstructured":"Higgins JP, Green S (2024) Cochrane handbook for systematic reviews of interventions version 6.5, Cochrane. Available from: https:\/\/training.cochrane.org\/handbook"},{"issue":"3","key":"4806_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00192-005-1340-3","volume":"17","author":"S Hill","year":"2006","unstructured":"Hill S, Khullar V, Wyndaele JJ, Lheritier K (2006) Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17(3):239\u201347. https:\/\/doi.org\/10.1007\/s00192-005-1340-3","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"6","key":"4806_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306\u20131315. https:\/\/doi.org\/10.1016\/j.eururo.2006.09.019","journal-title":"Eur Urol"},{"issue":"2","key":"4806_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50(2):317\u2013326. https:\/\/doi.org\/10.1016\/j.eururo.2006.03.057","journal-title":"Eur Urol"},{"issue":"3","key":"4806_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/luts.12132","volume":"9","author":"A Kim","year":"2017","unstructured":"Kim A, Lee KS, Jung R, Na S, Kim JC, Kim HG, Choo MS (2017) Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder. LUTS Lower Urinary Tract Symptoms 9(3):171\u2013175. https:\/\/doi.org\/10.1111\/luts.12132","journal-title":"LUTS Lower Urinary Tract Symptoms"},{"issue":"6","key":"4806_CR12","doi-asserted-by":"publisher","first-page":"1442.e9","DOI":"10.1016\/j.urology.2011.08.039","volume":"78","author":"C Moro","year":"2011","unstructured":"Moro C, Uchiyama J, Chess-Williams R (2011) Urothelial\/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. Urology 78(6):1442.e9\u201315. https:\/\/doi.org\/10.1016\/j.urology.2011.08.039","journal-title":"Urology"},{"issue":"1","key":"4806_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/nau.24839","volume":"41","author":"C Moro","year":"2022","unstructured":"Moro C, Phelps C, Veer V, Clark J, Glasziou P, Tikkinen KAO, Scott AM (2022) The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 41(1):127\u2013139. https:\/\/doi.org\/10.1002\/nau.24839","journal-title":"Neurourol Urodyn"},{"key":"4806_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.07.002","author":"C Moro","year":"2024","unstructured":"Moro C, Phelps C, Veer V, Jones M, Glasziou P, Clark J, Tikkinen KAO, Scott AM (2024) Cranberry juice, cranberry tablets, or liquid therapies for urinary tract infection: a systematic review and network meta-analysis. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2024.07.002","journal-title":"Eur Urol Focus"},{"issue":"7","key":"4806_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17512433.2020.1779056","volume":"13","author":"H Mostafaei","year":"2020","unstructured":"Mostafaei H, Shariat SF, Salehi-Pourmehr H, Janisch F, Mori K, Quhal F, Hajebrahimi S (2020) The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Rev Clin Pharmacol 13(7):707\u2013720. https:\/\/doi.org\/10.1080\/17512433.2020.1779056","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"4806_CR16","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0091270005279010","volume":"45","author":"DB Serra","year":"2005","unstructured":"Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A, Wang Y (2005) QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 45(9):1038\u20131047. https:\/\/doi.org\/10.1177\/0091270005279010","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4806_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1464-410X.2005.05343.x","volume":"95","author":"W Steers","year":"2005","unstructured":"Steers W, Corcos J, Foote J, Kralidis G (2005) An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 95(4):580\u2013586. https:\/\/doi.org\/10.1111\/j.1464-410X.2005.05343.x","journal-title":"BJU Int"},{"issue":"4","key":"4806_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.juro.2013.10.046","volume":"191","author":"PW Veenboer","year":"2014","unstructured":"Veenboer PW, Bosch JLHR (2014) Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 191(4):1003\u20131008. https:\/\/doi.org\/10.1016\/j.juro.2013.10.046","journal-title":"J Urol"},{"issue":"5","key":"4806_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/nau.25176","volume":"42","author":"V Veer","year":"2023","unstructured":"Veer V, Chess-William R, Moro C (2023) Antimuscarinic actions on bladder urothelium and lamina propria contractions are similar to those observed in detrusor smooth muscle preparations. Neurourol Urodyn 42(5):1080\u20131087. https:\/\/doi.org\/10.1002\/nau.25176","journal-title":"Neurourol Urodyn"},{"key":"4806_CR20","doi-asserted-by":"publisher","first-page":"1534517","DOI":"10.3389\/fphys.2025.1534517","volume":"16","author":"V Veer","year":"2025","unstructured":"Veer V, Chess-Williams R, Moro C (2025) Comparisons of urinary bladder responses to common antimuscarinics reveals unique effects of darifenacin. Front Physiol 16:1534517. https:\/\/doi.org\/10.3389\/fphys.2025.1534517","journal-title":"Front Physiol"},{"key":"4806_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.archger.2018.09.005","volume":"80","author":"SM Vouri","year":"2019","unstructured":"Vouri SM, Schootman M, Strope SA, Xian H, Olsen MA (2019) Antimuscarinic use and discontinuation in an older adult population. Arch Gerontol Geriatr 80:1\u201311. https:\/\/doi.org\/10.1016\/j.archger.2018.09.005","journal-title":"Arch Gerontol Geriatr"},{"issue":"3","key":"4806_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5213\/inj.2012.16.3.107","volume":"16","author":"S Yamada","year":"2012","unstructured":"Yamada S, Kuraoka S, Osano A, Ito Y (2012) Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. Int Neurourol J 16(3):107\u2013115. https:\/\/doi.org\/10.5213\/inj.2012.16.3.107","journal-title":"Int Neurourol J"},{"key":"4806_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889","author":"G Yeowell","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F (2018) Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2018-021889","journal-title":"BMJ Open"},{"issue":"4","key":"4806_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00345-005-0507-3","volume":"23","author":"N Zinner","year":"2005","unstructured":"Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 23(4):248\u2013252. https:\/\/doi.org\/10.1007\/s00345-005-0507-3","journal-title":"World J Urol"},{"issue":"1","key":"4806_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1368-5031.2005.00770.x","volume":"60","author":"N Zinner","year":"2006","unstructured":"Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F (2006) Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 60(1):119\u2013126. https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00770.x","journal-title":"Int J Clin Pract"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04806-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04806-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:37:38Z","timestamp":1776393458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04806-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04806-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics is not required for this analysis of already-published public research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}